MA29673B1 - N-hydroxyamides omega-substitues par des groupes tricycliques, servant d'inhibiteurs d'histone desacetylase, leur preparation et leur utilisation dans des formulations pharmaceutiques - Google Patents

N-hydroxyamides omega-substitues par des groupes tricycliques, servant d'inhibiteurs d'histone desacetylase, leur preparation et leur utilisation dans des formulations pharmaceutiques

Info

Publication number
MA29673B1
MA29673B1 MA30292A MA30292A MA29673B1 MA 29673 B1 MA29673 B1 MA 29673B1 MA 30292 A MA30292 A MA 30292A MA 30292 A MA30292 A MA 30292A MA 29673 B1 MA29673 B1 MA 29673B1
Authority
MA
Morocco
Prior art keywords
hydroxyamides
omega
inhibitors
histone deacetylase
substituted
Prior art date
Application number
MA30292A
Other languages
English (en)
Inventor
Antonio Guidi
Tula Dimoulas
Danilo Giannotti
Nicholas Harmat
Original Assignee
Menarini Int Operations Lu Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Menarini Int Operations Lu Sa filed Critical Menarini Int Operations Lu Sa
Publication of MA29673B1 publication Critical patent/MA29673B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/38—[b, e]- or [b, f]-condensed with six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D267/20—[b, f]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D281/16—[b, f]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/36—Seven-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/08—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

L'invention concerne de nouveaux N-hydroxyamides d'acides n-alkyle carboxyliques oméga substitués par des systèmes tricycliques appropriés caractérisés par un anneau central à sept éléments, présentant une activité analogue à celle d'inhibiteurs d'histone désacétylase (HDAC).
MA30292A 2005-03-15 2007-10-11 N-hydroxyamides omega-substitues par des groupes tricycliques, servant d'inhibiteurs d'histone desacetylase, leur preparation et leur utilisation dans des formulations pharmaceutiques MA29673B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000042 IT1362675B (it) 2005-03-15 2005-03-15 N-idrossiammidi -sostituiti con gruppi triciclici come inibitori dell'istone deacelitasi,loro preparazione ed impiego in formulazioni farmaceutiche

Publications (1)

Publication Number Publication Date
MA29673B1 true MA29673B1 (fr) 2008-08-01

Family

ID=36676439

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30292A MA29673B1 (fr) 2005-03-15 2007-10-11 N-hydroxyamides omega-substitues par des groupes tricycliques, servant d'inhibiteurs d'histone desacetylase, leur preparation et leur utilisation dans des formulations pharmaceutiques

Country Status (22)

Country Link
US (1) US20080275023A1 (fr)
EP (1) EP1863776A1 (fr)
JP (1) JP2008533088A (fr)
KR (1) KR20080003336A (fr)
CN (1) CN101142197A (fr)
AP (1) AP2007004170A0 (fr)
AR (1) AR053171A1 (fr)
AU (1) AU2006222883A1 (fr)
BR (1) BRPI0608549A2 (fr)
CA (1) CA2600521A1 (fr)
CO (1) CO6321131A2 (fr)
EA (1) EA013015B1 (fr)
IL (1) IL185879A0 (fr)
IT (1) IT1362675B (fr)
MA (1) MA29673B1 (fr)
MX (1) MX2007011071A (fr)
NI (1) NI200700222A (fr)
NO (1) NO20075229L (fr)
SA (1) SA06270133B1 (fr)
TW (1) TW200719900A (fr)
WO (1) WO2006097449A1 (fr)
ZA (1) ZA200708754B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0523040D0 (en) * 2005-11-11 2005-12-21 Cyclacel Ltd Combination
EP2343286B1 (fr) * 2006-10-28 2014-12-31 Methylgene, Inc. Dérivés de dibenzo[b,f][1,4]oxazépine en tant qu'inhibiteurs de l'histone désacétylase
AU2013205135B2 (en) * 2006-10-28 2015-11-05 Forum Pharmaceuticals Inc. Inhibitors of histone deacetylase
EP2102201B1 (fr) * 2006-12-11 2010-10-13 Merck Sharp & Dohme Corp. Sulfonamides de diazépine substitués utilisés en tant que modulateurs des récepteurs de sous-type 3 de la bombésine
JP2011102240A (ja) * 2008-02-29 2011-05-26 Univ Of Tokyo 三環性化合物
US8202989B2 (en) 2009-01-12 2012-06-19 Council Of Scientific And Industrial Research One step process for the preparation of substituted 5, 10-dihydrodibenzo [b,e][1, 4]diazepine-11-ones
WO2011130628A1 (fr) * 2010-04-16 2011-10-20 Curis, Inc. Traitement de cancers présentant des mutations k-ras
WO2012045194A1 (fr) * 2010-10-09 2012-04-12 Abbott Laboratories Benzodiazépinones à titre d'inhibiteurs de fak pour le traitement du cancer
RU2519546C1 (ru) * 2013-01-16 2014-06-10 Общество С Ограниченной Ответственностью "Биоинтегратор" (Ооо "Биоинтегратор") КОНЪЮГАТЫ И МАЛЫЕ МОЛЕКУЛЫ, ВЗАИМОДЕЙСТВУЮЩИЕ С РЕЦЕПТОРОМ CD16а
KR20150119390A (ko) 2013-02-19 2015-10-23 이칸 스쿨 오브 메디슨 엣 마운트 시나이 항암제로서의 삼환식 헤테로사이클
JP2017512766A (ja) 2014-03-11 2017-05-25 アイカーン スクール オブ メディスン アット マウント サイナイＩｃａｈｎ Ｓｃｈｏｏｌ ｏｆ Ｍｅｄｉｃｉｎｅ ａｔ Ｍｔ． Ｓｉｎａｉ 抗癌剤としてのトリシクリル−２−アミノシクロアルカノール由来スルホンアミド
JP2017507962A (ja) 2014-03-11 2017-03-23 アイカーン スクール オブ メディスン アット マウント サイナイＩｃａｈｎ Ｓｃｈｏｏｌ ｏｆ Ｍｅｄｉｃｉｎｅ ａｔ Ｍｔ． Ｓｉｎａｉ 限定された三環式スルホンアミド
WO2016083276A1 (fr) 2014-11-25 2016-06-02 Bayer Pharma Aktiengesellschaft Dérivés de pyridobenzodiazepinone substitués et leur utilisation
EP3226689B1 (fr) 2014-12-05 2020-01-15 Merck Sharp & Dohme Corp. Nouveaux composés tricycliques utilisés en tant qu'inhibiteurs d'enzymes idh mutantes
US10086000B2 (en) 2014-12-05 2018-10-02 Merck Sharp & Dohme Corp. Tricyclic compounds as inhibitors of mutant IDH enzymes
WO2016089797A1 (fr) 2014-12-05 2016-06-09 Merck Sharp & Dohme Corp. Composés tricycliques innovants servant d'inhibiteurs d'enzymes idh mutantes
GB201510010D0 (en) 2015-06-09 2015-07-22 King S College London PDD and BPD compounds
GB201514928D0 (en) 2015-08-21 2015-10-07 King S College London PDD compounds
US20180339985A1 (en) 2015-08-21 2018-11-29 Femtogenix Limited Pdd compounds
EP3347355B1 (fr) 2015-09-09 2022-07-13 Icahn School of Medicine at Mount Sinai Sulfonamides hétérotricycliques en tant qu'agents anti-cancéreux
WO2017044571A1 (fr) * 2015-09-09 2017-03-16 Icahn School Of Medicine At Mount Sinai Sulfonamides sultames tricycliques utilisés en tant qu'agents anticancéreux et neuroprotecteurs
EP3347350A1 (fr) 2015-09-09 2018-07-18 Icahn School of Medicine at Mount Sinai Sulfonamides hétérocycliques tricycliques contraints en tant qu'agents anti-cancéreux
CN105806973B (zh) * 2016-03-10 2019-01-18 中国医学科学院肿瘤医院 Uplc-ms/ms法测定人血浆中莎巴比星及其代谢产物m3的血药浓度
EP3749654A4 (fr) 2018-02-06 2021-11-03 The Board of Trustees of the University of Illinois Analogues de benzothiophène substitués en tant qu'agents de dégradation sélectifs du récepteur d'oestrogènes
KR102243465B1 (ko) * 2019-08-05 2021-04-22 리퓨어생명과학 주식회사 히스톤 아세틸트렌스퍼라제 p300 억제용 신규 화합물 및 이를 포함하는 항섬유화 조성물
KR102301274B1 (ko) * 2019-08-05 2021-09-14 리퓨어생명과학 주식회사 히스톤 아세틸트렌스퍼라제 p300 억제용 신규 화합물 및 이를 포함하는 항섬유화 조성물
WO2023020416A1 (fr) * 2021-08-16 2023-02-23 勤浩医药（苏州）有限公司 Composé tricyclique, composition pharmaceutique le comprenant et son utilisation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53121780A (en) * 1977-04-01 1978-10-24 Teikoku Hormone Mfg Co Ltd Dibenzazepin derivatives and process for their preparation
JPS6033110B2 (ja) * 1977-09-12 1985-08-01 帝国臓器製薬株式会社 ジベンズアゼピン誘導体
AR035455A1 (es) * 2001-04-23 2004-05-26 Hoffmann La Roche Derivados triciclicos de alquilhidroxamato , procesos para su elaboracion, composiciones farmaceuticas que los contienen, y el uso de dichos compuestos en la preparacion de medicamentos
EP1577301B1 (fr) * 2002-12-25 2012-09-12 Daiichi Sankyo Company, Limited Dérivés de cyclohexane à activité antithrombotique

Also Published As

Publication number Publication date
JP2008533088A (ja) 2008-08-21
EA013015B1 (ru) 2010-02-26
ITFI20050042A1 (it) 2006-09-16
TW200719900A (en) 2007-06-01
AP2007004170A0 (en) 2007-10-31
NO20075229L (no) 2007-11-08
CA2600521A1 (fr) 2006-09-21
US20080275023A1 (en) 2008-11-06
NI200700222A (es) 2008-07-24
EA200701969A1 (ru) 2008-02-28
AR053171A1 (es) 2007-04-25
MX2007011071A (es) 2007-10-08
ZA200708754B (en) 2008-10-29
IT1362675B (it) 2009-06-25
AU2006222883A1 (en) 2006-09-21
BRPI0608549A2 (pt) 2010-01-12
CN101142197A (zh) 2008-03-12
KR20080003336A (ko) 2008-01-07
IL185879A0 (en) 2008-01-06
EP1863776A1 (fr) 2007-12-12
SA06270133B1 (ar) 2009-05-16
WO2006097449A1 (fr) 2006-09-21
CO6321131A2 (es) 2011-09-20

Similar Documents

Publication Publication Date Title
MA29673B1 (fr) N-hydroxyamides omega-substitues par des groupes tricycliques, servant d'inhibiteurs d'histone desacetylase, leur preparation et leur utilisation dans des formulations pharmaceutiques
CR9430A (es) N-hidroxiamidas omega-sustituidas con grupos triciclos como inhibidores de histona desacetilasa, su preparacion y uso en formulaciones farmaceuticas
CY1118191T1 (el) Αναλογα δεοξυνοζιριμυκινης και οι χρησεις τους ως αναστολεις γλυκοζυλοκεραμιδασης
DK1781277T3 (da) Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol
CL2013001712A1 (es) Compuestos derivados de n-(1h-indazol-4-il)imidazo[1,2-a]piridin-3-carboxamida, inhbidores de la tirosina quinasa receptora de tipo iii; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades inflamatorias, cardiovasculares, fibrosis, trastornos autoinmunes, dolor, quemaduras.
CL2004000526A1 (es) Compuestos derivados de dibenzofurano, carbazoles, inhibidores de fosfodiesterasa tipo 4; procedimiento de preparacion; y su uso en el tratamiento de trastornos y condiciones inflamatorias, del sistema nervioso central y diabetes insulino resistente.
CY1118179T1 (el) Φαρμακευτικη συνθεση
EA200970374A1 (ru) Лечение антиаритмическими средствами и омега-3 жирными кислотами и их комбинированным продуктом
EA200800100A1 (ru) Соединения азаиндазола и способы применения
PE20091394A1 (es) Un compuesto de alfa-(n-sulfonamido) acetamida con un inhibidor de produccion de peptido beta amiloide
MY142589A (en) Benzimidazole derivatives : preparation and pharmaceutical applications
WO2007061862A3 (fr) 2-ceto-oxazoles en tant que modulateurs d'amide d'acide gras hydrolase
UY28330A1 (es) Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
FR2983409B1 (fr) Comprime susceptible de lutter contre le detournement par voie injectable
ATE441628T1 (de) Tricyclische hydroxamat- und benzamidderivate, zusammensetzungen und verfahren
WO2007014124A3 (fr) Formes posologiques et preparations a charge medicamenteuse elevee
UA99645C2 (ru) Гель, имеющий противовоспалительное и противоаллергическое действие
NO330984B1 (no) Aminosyre-fenoksyestere, fremgangsmate for fremstilling av slike, mellomprodukter i synteseveien, farmasoytisk preparat omfattende slike samt anvendelse av slike for fremstilling av farmasoytisk preparat for behandling av sykdom
MA33463B1 (fr) Compositions à dose pharmaceutique solide fixe comprenant de l'irbésartan et de l'amlodipine, leur préparation et leur application thérapeutique
MX2012001853A (es) Composicion farmaceutica para aliviar el dolor.
SE0302488D0 (sv) New combination
EA200701221A1 (ru) Режим применения кладрибина для лечения рассеянного склероза
EE05357B1 (et) Tablett, mis sisaldab v„hemalt kahte eristatavat segmenti, ning selle kasutamine
MA49839B1 (fr) Inhibiteurs bicycliques de la histone déacétylase
CY1111899T1 (el) Καινοφανη παραγωγα πυρρολης με δραστηριοτητα αναστολεα της απακετυλασης της ιστονης